Nilotinib and imatinib inhibit cytarabine cellular uptake: Implications for combination therapy-Reference-Cited by-同舟云学术

Nilotinib and imatinib inhibit cytarabine cellular uptake: Implications for combination therapy

Published:2012-10 Issue:10 Volume:36 Page:1311-1314
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Naud Josy S.,Ghani Karim,de Campos-Lima Pedro O.,Caruso Manuel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference19 articles.

1. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia;Weisberg;Nat Rev Cancer,2007

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

3. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate;Kantarjian;Clin Cancer Res,2002

4. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias;Ottmann;Blood,2002

5. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL;Kantarjian;N Engl J Med,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers;Cancers;2021-02-25

2. Development and validation of a sensitive LC–MS/MS method for simultaneous determination of eight tyrosine kinase inhibitors and its application in mice pharmacokinetic studies;Journal of Pharmaceutical and Biomedical Analysis;2018-01

3. Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors;Journal of Biological Chemistry;2016-09

4. Comparison of Human Nucleoside Transporter Interactions with BCR-ABL Kinase Inhibitors;Annals of Oncology;2015-03

5. Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters;Expert Opinion on Drug Metabolism & Toxicology;2015-01-29